Long-term efficacy of oral deferiprone in management of iron overload in beta thalassemia major

Hematology

Volumn 13, Issue 2, 2008, Pages 77-82

  Goel, Himanshu ^a   Girisha, K M ^a   Phadke, Shubha R ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Deferiprone; Iron chelation; Pharmacogenetics; Serum ferritin; Thalassemia major

Indexed keywords

DEFERIPRONE; FERRITIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; BLOOD TRANSFUSION; CHILD; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; ERYTHROCYTE CONCENTRATE; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; IRON CHELATION; IRON OVERLOAD; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; SPLENECTOMY; THALASSEMIA MAJOR; THROMBOCYTOPENIA; TREATMENT DURATION; TREND STUDY; VOMITING;

ADOLESCENT; BETA-THALASSEMIA; CHILD; DISEASE MANAGEMENT; DRUG EVALUATION; FEMALE; FERRITINS; HUMANS; IRON OVERLOAD; MALE; PROGNOSIS; PYRIDONES; TREATMENT OUTCOME;

EID: 48749087262     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453308X315924     Document Type: Article

References (15)

1. Porter JB. Practical management of iron overload. Br J Haematol 2001; 115: 239-252.
2. Matsui D, Klein J, Hermann C et al. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clin Pharmacol Ther 1991; 50: 294-298.
3. Ceci A., Baiardi P, Felisi M et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002; 118: 330-336.
4. Al-Refaie FN, Wonke B, Hoffbrand AV et al. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood 1992; 80: 593-599.
5. Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy A et al. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. Br J Haemalol 1990; 76: 550-553.
6. Barman BJA, Foster RH. Deferiprone: A review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. Drugs 1999; 58: 553-578
7. Agarwal MB, Gupte SS, Vasandani D et al. Efficacy and safety of 1,2,-dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload. J Assoc Physicians India 1991; 39: 669-672.
8. Agarwal MB, Gupte SS, Viswanathan C. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 1992; 82: 460-466.
9. Al-Refaie FN, Hershko C, Hoffbrand AV. Results of long-term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995; 91: 224-229.
10. Al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1. Br J Haematol 1992; 82: 431-436.
11. Pootrakul P, Sirankapracha P, Sankote J, Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 2003; 122: 305-310.
12. Rombos Y, Tzanetea R, Konstantopoulos K. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica 2000; 85: 115-117.
13. Hoffbrand AV, Al-Refaie F, Davis B. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998; 91: 295-300.
14. Kontoghiorghes G J, Bartlett AN, Hoffbrand AV et al. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies. Br J Haematol 1990; 76: 295-300.
15. Olivieri NF, Brittenham GM, Matsui D et al. Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med 1995; 332: 918-922.